Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.

被引：1
|
作者：
Akce, Mehmet
Alese, Olatunji B.
Shaib, Walid Labib
Wu, Christina Sing-Ying
Lesinski, Gregory B.
El-Rayes, Bassel F.
机构：
[1] Winship Canc Inst, Atlanta, GA USA
[2] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH USA
[3] Richard J Solove Res Inst, Columbus, OH USA
[4] Emory Univ Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.TPS526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS526
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies: Results of the dose-escalation phase
    Akce, Mehmet
    Alese, Olatunji B.
    Shaib, Walid Labib
    Wu, Christina
    Lesinski, Gregory B.
    El-Rayes, Bassel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [2] Phase Ib study of pembrolizumab and XL888 in patients with advanced colorectal cancer
    Alese, O.
    Gbolahan, O. B.
    McCook-Veal, A.
    Coleman, K.
    Greene, E.
    Horvat, N.
    Switchenko, J.
    Lesinski, G.
    El-Rayes, B. F.
    ANNALS OF ONCOLOGY, 2024, 35 : S25 - S25
  • [3] XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial
    Phillips, Maggie J.
    Alese, Olatunji B.
    Horvat, Natalie K.
    Greene, Emily
    Gbolahan, Olumide B.
    Coleman, Kathleen
    Doxie, Deon B.
    Parihar, Vaunita
    Mahdi, Zaid K.
    McCook-Veal, Ashley
    Switchenko, Jeffrey M.
    Diab, Maria
    Herting, Cameron J.
    Paulos, Chrystal M.
    El-Rayes, Bassel F.
    Lesinski, Gregory B.
    ONCOIMMUNOLOGY, 2025, 14 (01):
  • [4] INVESTIGATING THE CLINICAL SAFETY, EFFICACY, AND IMMUNE MODULATION OF COMBINED XL888 AND PEMBROLIZUMAB IN METASTATIC GASTROINTESTINAL MALIGNANCIES
    Herting, Cameron
    Zhang, Yuchen
    Doxie, Deon
    Farren, Matthew
    Ware, Michael
    Alese, Olatunji
    Wu, Christina
    Shaib, Walid
    Akce, Mehmet
    Zaidi, Mohammad
    Ruggieri, Amanda
    Dhodapkar, Madhav
    Dhodapkar, Kavita
    Sarmiento, Juan
    Ahmed, Rafi
    Maithel, Shishir
    El-rayes, Bassel
    Lesinski, Gregory
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A202 - A203
  • [5] Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
    Hubbard, Joleen Marie
    Kim, George P.
    Bored, Mitesh J.
    Qin, Rui
    Lensing, Janet
    Wright, John Joseph
    Erlichman, Charles
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
    Hubbard, Joleen Marie
    Kim, George P.
    Borad, Mitesh J.
    Qin, Rui
    Lensing, Janet
    Wright, John Joseph
    Erlichman, Charles
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [7] A phase Ib trial of alpelisib and weekly cisplatin in patients with solid tumor malignancies.
    Tsang, Erica S.
    Aggarwal, Rahul Raj
    Dhawan, Mallika Sachdev
    Pacaud, Romain
    Fattah, Delaire
    Thomas, Scott
    Grabowsky, Jennifer A.
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Phase I trial of SNS-595 in patients with advanced malignancies.
    Advani, R
    Gordon, M
    Hurwitz, H
    Mendelson, D
    Wakelee, H
    Ebbinghaus, S
    Hoch, U
    Silverman, J
    Havrilla, N
    Adelman, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 159S - 159S
  • [9] Phase I trial of oral etoposide in combination with celecoxib in patients with advanced malignancies.
    Luu, TH
    Twardowski, P
    Leong, L
    Lim, D
    Morgan, R
    McNamara, M
    Portnow, J
    Ruel, C
    Shibata, S
    Synold, T
    Doroshow, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 241S - 241S
  • [10] Phase I/II trial with 111In-pentetreotide in patients with advanced malignancies.
    Argiris, A
    Peccerillo, K
    Murren, JR
    Cornelius, E
    Modlin, IM
    GASTROENTEROLOGY, 2000, 118 (04) : A515 - A515
12345